Patents Assigned to UNIVERSITE DE NICE
-
Patent number: 11577082Abstract: Devices and methods for the stimulation of neural signaling of an apical splenic nerve, the device having a transducer for placement on or around the apical splenic nerve, and a signal generator to generate a signal that stimulates or inhibits the neural activity of the apical splenic nerve to produce a physiological response. The transducer has at least one electrode, and the signal generator is a voltage or current source. The stimulation electrical signal has a frequency of between 1 Hz and 50 Hz.Type: GrantFiled: November 8, 2017Date of Patent: February 14, 2023Assignees: Galvani Bioelectronics Limited, GlaxoSmithKline Intellectual Property Development Limited, Université de Nice Sophia-Antipolis, Centre Nationale de La Recherche ScientifiqueInventors: Philippe Blancou, Nicolas Glaichenhaus, Arun Sridhar
-
Patent number: 11236287Abstract: The invention relates to 2-octylcyclopropyl-1-carboxylic acid, in particular in the form of one of the isomers thereof in isolated form or in the form of a mixture of at least two of said isomers. The invention further relates to a method for synthesizing 2-octylcyclopropyl-1-carboxylic acid or at least one of the isomers thereof. Finally, the invention relates to the use of 2-octylcyclopropyl-1-carboxylic acid or of one of said isomers in isolated form or of one of the mixtures of at least two of the isomers thereof, as a perfuming agent. The invention further relates to the compositions including 2-octylcyclopropyl-1-carboxylic acid or one of said isomers in isolated form or one of the mixtures of at least two of the isomers thereof, as a perfuming agent.Type: GrantFiled: November 18, 2015Date of Patent: February 1, 2022Assignees: Albert Vielle, Centre National de la Recherche Scientifique (CNRS), Universite de NiceInventors: Nicolas Baldovini, Céline Cerutti-Delasalle
-
Patent number: 11220527Abstract: Disclosed are new peptides derived from the neurotensin receptor 3 (NTSR3), and to their use, particularly in the treatment of various diseases, especially depression.Type: GrantFiled: October 11, 2017Date of Patent: January 11, 2022Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE NICE SOPHIA ANTIPOLISInventors: Jean Mazella, Marc Borsotto, Catherine Heurteaux, Alaeddine Djillani, Sébastien Moreno, Mariel Pietri
-
Publication number: 20200264166Abstract: A process for isolating or extracting rare cells from a biological sample comprising filtering a biological sample, which may be treated or diluted, through a filter that has a pore size, pore density or other physical properties that retain rare cells, but which permits other kinds of cells to pass through the filter. This process also comprises multiple analyses performed on rare cells after their extraction or isolation by filtration to diagnostically identify the presence of rare cells in a biological sample and to use their diagnostic identification and molecular characterization for diagnostic purposes such as for early diagnosis of diseases, namely for early diagnosis of cancer and to select, guide, monitor treatments and in particular to select targeted treatments and to monitor the response and/or resistance to them.Type: ApplicationFiled: January 17, 2020Publication date: August 20, 2020Applicants: RARECELLS SAS, UNIVERSITE DE NICE SOPHIA ANTIPOLIS, CENTRE HOSPITALIER UNIVERSITAIRE DE NICE, UNIVERSITE PARIS DESCARTES, Assistance Publique-Hopitaux de Paris (AP-HP), Institut National de la Sante et de la Recherche Medicale (Inserm)Inventors: Patrizia PATERLINI-BRECHOT, Paul HOFMAN, Sophie Marie Genevieve LAGET, Thierry CAPIOD
-
Patent number: 10739356Abstract: Disclosed is a method for assessing the prognosis of idiopathic membranous nephropathy in a body fluid sample from a human subject, based on profiling PLA2R1 epitopes recognized by autoantibodies in the sample. The method further relates to analysis of PLA2R1 epitope spreading amongst three PLA2R1 domains (Cys R, CTLD1 and CTLD7) that are recognized by anti-PLA2R1 autoantibodies, two of which (CTLD1 and CTLD7) are more closely associated with active idiopathic membranous nephropathy and likely linked by a mechanism of epitope spreading.Type: GrantFiled: July 8, 2016Date of Patent: August 11, 2020Assignees: Université de Nice Sophia Antipolis, Centre National de la Recherche Scientifique (CNRS), CHU de NiceInventors: Vincent Louis Marie Esnault, Barbara Polski, Gérard Jean Frantz Lambeau, Guillaume Dolla
-
Patent number: 10678970Abstract: The invention is a method for exploitation of a sedimentary basin containing hydrocarbons, including optimized scaling of the geological model. Based on categorical property measurements, a first meshed representation of a formation is constructed reflecting the categorical property measurements. At least one second meshed representation having a lower resolution is constructed by assigning a categorical property value to each mesh of the second representation corresponding to a group of meshes of the first representation and storing parameters for changing from the second representation to the first representation with those change parameters enabling reconstitution of the first representation.Type: GrantFiled: May 31, 2017Date of Patent: June 9, 2020Assignees: IFP ENERGIES NOUVELLES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE NICEInventors: Marc Antonini, Frédéric Payan, Sebastien Schneider, Laurent Duval, Jean-Luc Peyrot
-
Patent number: 10644690Abstract: An electronic circuit includes at least one first multi-gate transistor including a first gate and a second gate different from the first gate; and a regulation unit designed to measure a variable representing the drain-source voltage of the first transistor and to apply a polarization potential as a function of the variable to the second gate of the first transistor.Type: GrantFiled: September 21, 2016Date of Patent: May 5, 2020Assignees: Commissariat à l'Énergie Atomique et aux Énergies Alternatives, UNIVERSITE DE NICE SOPHIA ANTIPOLISInventors: Patrick Audebert, Emeric De Foucauld, Yves Leduc, Gilles Jacquemod, Zhaopeng Wei, Philippe Lorenzini
-
Patent number: 10610504Abstract: The present invention relates to methods of generating a population of beta cells from a population of alpha cells, by contacting said population of alpha cells with GABA or a GABA receptor agonist, in combination with a monoclonal glucagon neutralizing antibody or other alpha cell mass regulating compounds, for an improved diabetes therapy.Type: GrantFiled: December 23, 2015Date of Patent: April 7, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE NICE SOPHIA ANTIPOLIS-GRAND CHÂTEAUInventors: Jacob Hecksher-Sørensen, Patrick Collombat
-
Publication number: 20190290913Abstract: Stimulation of neural signalling of an apical splenic nerve can modulate pro- and anti-inflammatory molecules levels, thereby reducing inflammation and providing ways of treating inflammatory disorders.Type: ApplicationFiled: November 8, 2017Publication date: September 26, 2019Applicants: GALVANI BIOELECTRONICS LIMITED, UNIVERSITÉ DE NICE SOPHIA-ANTIPOLIS, CENTRE NATIONALE DE LA RECHERCHE SCIENTIFIQUEInventors: Philippe BLANCOU, Nicolas GLAICHENHAUS, Arun SRIDHAR
-
Patent number: 10347984Abstract: Antenna system comprising at least two radiating elements, a first line for neutralizing electromagnetic coupling between the at least two radiating elements, at least one radiofrequency power supply line for each radiating element and at least one short-circuiting line to a ground plane of the antenna system per radiating element, characterized in that the antenna system further comprises: at least one second line for neutralizing electromagnetic coupling between said at least two radiating elements; elements for activating at least some of the neutralization lines; and in that the activation elements are configured to selectively activate or deactivate at least some of the neutralization lines, in such a way that depending on the activation/deactivation thereof the neutralization lines provide a maximum neutralization of the electromagnetic coupling of the radiating elements for a plurality of different frequencies.Type: GrantFiled: May 19, 2015Date of Patent: July 9, 2019Assignees: UNIVERSITE DE NICE SOPHIA ANTIPOLIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRSInventors: Philippe Le Thuc, Robert Staraj, Aliou Diallo, Mickaêl Jeangeorges
-
Patent number: 10323210Abstract: The invention relates to a vetiveryl ester comprising at least 0.5 weight percent of secondary alcohol compounds with respect to the total weight of the vetiveryl ester and to a process for the preparation a vetiveryl ester, the process comprising: providing a vetiver oil, at least one enzyme preparation and at least one acylating compound; and allowing sufficient time for the enzyme preparation to esterify the alcohol compounds of the vetiver oil with the acylating compound. The invention also relates to a vetiveryl ester obtainable by the above process, a fragrance composition comprising an above-mentioned vetiveryl ester and the use of an above-mentioned vetiveryl ester for the preparation of a perfumed product.Type: GrantFiled: May 30, 2016Date of Patent: June 18, 2019Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, UNIVERSITÉ DE NICE-SOPHIA ANTIPOLISInventors: Sylvain Antoniotti, Jean-Jacques Filippi, Irene Notar Francesco, Jade Ramilijaona
-
Patent number: 10206867Abstract: An alcoholic extract of aerial parts of Solidago virgaurea subsp. alpestris, the method of production thereof, a cosmetic or dermatological composition containing it, as well as cosmetic and dermatological uses thereof, notably in the treatment of signs of skin ageing.Type: GrantFiled: November 25, 2016Date of Patent: February 19, 2019Assignees: CHANEL PARFUMS BEAUTE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, UNIVERSITE DE NICE SOPHIA ANTIPOLISInventors: Serge Holderith, Anais Tromeur, Irina Berlin, Xavier Fernandez, Alexandre Casale, Johannes Grillari, Ingo Lammermann, Florian Gruber, Marie-Sophie Narzt, Gaëlle Gendronneau
-
Patent number: 10208351Abstract: The present invention concerns an in vitro method of diagnosis or prognosis of an atherosclerosis-related disorder by detecting a small Y RNA (s-RNY), as well as the use of an inhibitor of s-RNY as a medicament against atherosclerosis-related disorders. The invention also concerns a method for screening for a compound suitable for the treatment of an atherosclerosis-related disorder.Type: GrantFiled: October 20, 2014Date of Patent: February 19, 2019Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PAUL SABATIER TOULOUSE III, UNIVERSITE DE NICE SOPHIA ANTIPOLISInventors: Michele Trabucchi, Laurent Martinez, Emanuela Repetto
-
Patent number: 10210744Abstract: An alarm device comprises an RFID circuit that is configured to store identification information and is coupled to an antenna designed to receive and to emit, from and to an RFID reader, signals at the frequency of the RFID reader, and a switch coupled to the antenna and able to be activated by a user, enabling the antenna to be matched to the frequency of the RFID reader. The alarm device comprises the RFID circuit, the antenna and the switch designed to be incorporated into an object worn by a user, and enable the alarm to be activated discreetly.Type: GrantFiled: May 4, 2016Date of Patent: February 19, 2019Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE NICE-SOPHIA ANTIPOLIS, ENGINEERING SECURITYInventors: Aliou Diallo, Robert Staraj, Philippe Le Thuc, Imen Cherif
-
Patent number: 10164573Abstract: A differential-logic logic circuit chained with another differential-logic circuit comprises a first logic cell composed of back-gate transistors, the first cell having a first input for receiving a first input signal and having an output for delivering a first output signal, and a second logic cell complementary to the first cell, composed of back-gate transistors, the second cell having as many inputs as the first cell, each input able to receive an input signal complementary to the respective input signal of the first cell, the second cell having an output for delivering a second output signal complementary to the first output signal of the first cell. The first output signal of the first cell is applied to the back gate of each transistor of the second cell, and the second output signal of the second cell is applied to the back gate of each transistor of the first cell.Type: GrantFiled: April 8, 2016Date of Patent: December 25, 2018Assignees: UNIVERSITE DE NICE, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVESInventors: Gilles Fernand Jacquemod, Emeric De Foucauld, Alexandre Benjamin Fonseca, Yves Leduc, Philippe Bernard Pierre Lorenzini
-
Publication number: 20180254775Abstract: An electronic circuit includes at least one first multi-gate transistor including a first gate and a second gate different from the first gate; and a regulation unit designed to measure a variable representing the drain-source voltage of the first transistor and to apply a polarization potential as a function of the variable to the second gate of the first transistor.Type: ApplicationFiled: September 21, 2016Publication date: September 6, 2018Applicants: Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Universite De Nice Sophia AntipolisInventors: Patrick AUDEBERT, Emeric DE FOUCAULD, Yves LEDUC, Gilles JACQUEMOD, Zhaopeng WEI, Philippe LORENZINI
-
Patent number: 10047156Abstract: The invention provides an isolated antibody or a fragment thereof, which is directed to the human chemokines CXCL1, CXCL7 and CXCL8, said antibody or fragment being capable of binding to the human chemokine CXCL1 with an equilibrium dissociation constant (KD) of at most 16 nM, to the human chemokine CXCL7 with an equilibrium dissociation constant (KD) of at most 5 nM and to the human chemokine CXCL8 with an equilibrium dissociation constant (KD) of at most 45 nM, as determined by surface plasmon resonance. The invention also provides some applications of said isolated antibody.Type: GrantFiled: May 19, 2014Date of Patent: August 14, 2018Assignees: Centre National De La Recherche Scientifique (CNRS), Universite de Nice Sophia AntipolisInventors: Gilles Pages, Renaud Grepin
-
Publication number: 20180148666Abstract: The invention relates to a vetiveryl ester comprising at least 0.5 weight percent of secondary alcohol compounds with respect to the total weight of the vetiveryl ester and to a process for the preparation a vetiveryl ester, the process comprising: providing a vetiver oil, at least one enzyme preparation and at least one acylating compound; and allowing sufficient time for the enzyme preparation to esterify the alcohol compounds of the vetiver oil with the acylating compound. The invention also relates to a vetiveryl ester obtainable by the above process, a fragrance composition comprising an above-mentioned vetiveryl ester and the use of an above-mentioned vetiveryl ester for the preparation of a perfumed product.Type: ApplicationFiled: May 30, 2016Publication date: May 31, 2018Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS, UNIVERSITÉ DE NICE-SOPHIA ANTIPOLISInventors: Sylvain Antoniotti, Jean-Jacques Filippi, Irene Notar Francesco, Jade Ramilijaona
-
Patent number: 9914691Abstract: The first subject matter of the invention is the (3R) epimer of octahydro-7,7-dimethyl-8-methylene-1H-3a,6-methanoazulen-3-yl acetate [(octahydro-7,7-dimethyl-8-methylene-[3R,3aR,6R,8aR]-1H-3a,6-methanoazulen-3-yl acetate) or (R)-norzizaenylacetate] of formula I (I). The subject matter of the invention is also compositions comprising (R)norzizaenyl acetate and also a novel synthesis process and the use of said ester.Type: GrantFiled: June 25, 2014Date of Patent: March 13, 2018Assignees: ROBERTET SA, UNIVERSITE DE NICE SOPHIA ANTIPOLIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Jean-Jacques Filippi, Emilie Belhassen, Nicolas Baldovini, Hugues Brevard
-
Patent number: 9800399Abstract: A device and a method for synchronizing entanglement sources with optical pump in a quantum communication network are disclosed. The device includes a pulsed optical source allowing emission of telecom wavelength optical clock pulses distributed in parallel to the entanglement sources to ensure synchronization of the entanglement sources; and for each of the entanglement sources, a frequency conversion device, allowing frequency conversion of the distributed telecom wavelength optical clock pulses to a wavelength adapted to optically pump the entanglement source. The method includes emitting and distributing in parallel, to the entanglement sources, telecom wavelength optical clock pulses; and locally, at each of the entanglement sources, frequency converting the telecom wavelength optical clock pulses to a wavelength adapted to optically pump the entanglement source.Type: GrantFiled: September 28, 2012Date of Patent: October 24, 2017Assignees: Centre National de la Recherche Scientifique—CNRS, Université de Nice Sophia AntipolisInventors: Sébastien Tanzilli, Virginia D'Auria, Olivier Alibart, Anthony Christophe Mickaël Martin, Laurent Labonte